Core Insights - Qualigen Therapeutics, Inc. has announced the granting of a patent titled "Substituted Naphthalene Diimides and Their Use" for its drug QN-302, developed by Professor Stephen Neidle and his team at University College of London [1] - The patent covers the product and its manufacturing methods, with coverage extending to over 20 countries in Europe, as well as India, China, and Russia, expiring in 2040 [2] - CEO Kevin Richardson II emphasized that the extensive patent coverage strengthens the company's position in drug development, particularly for treating pancreatic and gastrointestinal cancer [2] Patent Coverage - The granted patents cover a significant portion of the European population, with over 20 countries included [2] - Similar patent protections have been secured in India, China, and Russia, enhancing the global reach of QN-302 [2] - The expiration of these patents is set for 2040, providing long-term protection for the product [2] Company Strategy - The company plans to provide periodic updates on new patents, indicating ongoing efforts in intellectual property management [2] - The strong patent coverage is expected to facilitate the market introduction of QN-302, aimed at treating patients with specific types of cancer [2]